Do statins lower testosterone and does it matter?

por Sniderman, Allan D, Thanassoulis, George
Publicado 2013

Apolipoprotein B in cardiovascular risk assessment

por Ahmad, Maud, Sniderman, Allan D., Hegele, Robert A.
Publicado 2023

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol

por Contois, John H., Langlois, Michel R., Cobbaert, Christa, Sniderman, Allan D.
Publicado 2023

Elevated troponin I levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients

por Alam, Ahsan, Palumbo, Andrea, Mucsi, Istvan, Barré, Paul E, Sniderman, Allan D
Publicado 2013

Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated

por Sniderman, Allan D., Thanassoulis, George, Wilkins, John T., Furberg, Curt D., Pencina, Michael
Publicado 2018

Regulation of plasma LDL: the apoB paradigm

por Sniderman, Allan D., De Graaf, Jacqueline, Couture, Patrick, Williams, Ken, Kiss, Robert S., Watts, Gerald F.
Publicado 2009

Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk...

por Glavinovic, Tamara, Thanassoulis, George, de Graaf, Jacqueline, Couture, Patrick, Hegele, Robert A., Sniderman, Allan D.
Publicado 2022

Diabetes, Abdominal Adiposity, and Atherogenic Dyslipoproteinemia in Women Compared With Men

por Williams, Ken, Tchernof, Andre, Hunt, Kelly J., Wagenknecht, Lynne E., Haffner, Steven M., Sniderman, Allan D.
Publicado 2008

The causal exposure model of vascular disease

por Sniderman, Allan D., Lawler, Patrick R., Williams, Ken, Thanassoulis, George, de Graaf, Jacqueline, Furberg, Curt D.
Publicado 2011

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol

por Sniderman, Allan D., Islam, Shofiqul, McQueen, Matthew, Pencina, Michael, Furberg, Curt D., Thanassoulis, George, Yusuf, Salim
Publicado 2016

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

por Nelson, Adam J., Sniderman, Allan D., Ditmarsch, Marc, Dicklin, Mary R., Nicholls, Stephen J., Davidson, Michael H., Kastelein, John J. P.
Publicado 2022

Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low‐Density Lipoprotein Cholesterol—The Framingham Heart Study

por Afshar, Mehdi, Rong, Jian, Zhan, Yang, Chen, Hao Yu, Engert, James C., Sniderman, Allan D., Larson, Martin G., Vasan, Ramachandran S., Thanassoulis, George
Publicado 2020

Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles

por Guo, Wen, Pencina, Karol M, Furtado, Jeremy D, Sacks, Frank M, Vaisar, Tomas, Cheng, Ming, Sniderman, Allan D, Page, Stephanie T, Bhasin, Shalender
Publicado 2022

Quantifying Importance of Major Risk Factors for Coronary Heart Disease

por Pencina, Michael J., Navar, Ann Marie, Wojdyla, Daniel, Sanchez, Robert J., Khan, Irfan, Elassal, Joseph, D’Agostino, Ralph B., Peterson, Eric D., Sniderman, Allan D.
Publicado 2019

Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)

por Pallazola, Vincent A., Sathiyakumar, Vasanth, Park, Jihwan, Vakil, Rachit M., Toth, Peter P., Lazo-Elizondo, Mariana, Brown, Emily, Quispe, Renato, Guallar, Eliseo, Banach, Maciej, Blumenthal, Roger S., Jones, Steven R., Marais, David, Soffer, Daniel, Sniderman, Allan D., Martin, Seth S.
Publicado 2019